[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633823":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":13,"studyPopulation":17,"armGroups":18,"interventions":13,"overallOfficials":22,"centralContacts":27,"locations":33,"responsibleParty":54,"collaborators":56,"id":62,"slug":13,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":63,"sex":69,"minAge":70,"maxAge":13,"enrollmentInfo":71,"targetDuration":13,"studyType":74,"phases":13,"briefSummary":75,"conditions":76,"keywords":13,"overallStatus":35,"whyStopped":13,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Institut fuer Frauengesundheit","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Abemaciclib persistence rate","Abemaciclib persistence rate (defined as ongoing abemaciclib therapy)","6 months after therapy start",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"COHORT","RETROSPECTIVE","Patients will be selected from up to 30 study sites across Germay. Sites will be selected from certified breast cancer centers that have experience providing adjuvant treatment to breast cancer patients.",[19],{"label":20,"type":13,"description":21,"interventionNames":13},"High-risk HR+\u002FHER2- early breast cancer patients","High-risk HR+\u002FHER2- early breast cancer patients under abemaciclib therapy",[23],{"name":24,"affiliation":25,"role":26},"Peter A. Fasching, Prof. Dr. med.","Department of Obstetrics and Gynaecology, Uniklinikum Erlangen","STUDY_CHAIR",[28],{"name":29,"role":30,"phone":31,"phoneExt":13,"email":32},"Sponsor's study office","CONTACT","+49 15739466438","studien@ifg-erlangen.de",[34],{"facility":25,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"RECRUITING","Erlangen","Bavaria","91054","Germany","DE",{"type":42,"coordinates":43},"Point",[44,45],11.00783,49.59099,{"lat":45,"lon":44},[48,52],{"name":49,"role":30,"phone":50,"phoneExt":13,"email":51},"Study Center","+49 9131 8533572","fk-studienzentrale@uk-erlangen.de",{"name":24,"role":53,"phone":13,"phoneExt":13,"email":13},"PRINCIPAL_INVESTIGATOR",{"type":55,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR",[57,60],{"name":58,"class":59},"Lilly Deutschland GmbH Germany","UNKNOWN",{"name":61,"class":59},"AGO-B Breast Study Group","100633823",false,"NCT07531693","Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer","Patient Relevant Outcomes Improvement Program in High Risk HR-positive Breast Cancer","PROSPER","Inclusion Criteria:\n\n* Femal patients age 18 or older at time of informed consent\n* Confirmed diagnosis of HR+\u002FHER2- early breast cancer (no distant metastasis)\n* Prescribed abemaciclib therapy according to the Summary of Product Characteristics (SmPC)\n* Abemaciclib therapy occured between January 1st, 2023 and June 30th, 2025\n\nExclusion Criteria:\n\n* Locally advanced or metastatic breast cancer\n* Male patients\n* Patients with contraindication(s) for abemaciclib therapy according to SmPC","FEMALE","18 Years",{"count":72,"type":73},200,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate how persistently patients with high-risk early breast cancer take abemaciclib 6 months after therapy start. To this end, researchers will perform a retrospective analysis of therapy data.",[77],"HR+\u002FHER2- Early Breast Cancer","2026-05-11",{"date":80,"type":81},"2026-05-14","ACTUAL",{"date":83,"type":81},"2026-02-19",{"date":85,"type":73},"2027-03",{"name":5,"class":6},1]